Joel Wayment discusses the implications of the growing cell and gene therapy market on pharma supply chains. The rise in cell ...

In this week’s Pharma Pulse, GEODIS’ cold chain expansion in the Midwest, a potential multi-billion dollar shift in cell therapy, and the White House’s new push for psychedelic mental health ...

discusses today's key risks in the pharma supply chain, and how to prevent disruptions.

Joydeep Ganguly evaluates 4IR tools, data strategy, and why end-to-end thinking will define pharma supply chain ...

Pharmaceutical cold chain logistics is entering a phase where data quality and decision speed matter as much as physical ...

Following his keynote address at LogiPharma Europe 2026, Nico Vandaele, professor of Operations Research & Operations ...

Risk concentrates at transfer points and the final mile, where multiple touchpoints, tight delivery windows, and site-specific requirements can rapidly convert routine moves into service failures.

A bonded CFS footprint in a major North American freight gateway supports faster customs processing and secure short-term stowage for in-transit pharmaceutical cargo. Dedicated temperature-controlled ...

Regulatory expectations increasingly demand evidence of in-transit control, emphasizing data integrity, auditability, and ...

Eli Lilly has entered a definitive agreement to acquire Kelonia Therapeutics for up to $7 billion. The centerpiece of the ...